Session 12C: The new front line: Biotechnology as strategic infrastructure
Tracks
Track 3
| Friday, October 23, 2026 |
| 2:55 PM - 3:40 PM |
| Discovery & Advanced Therapeutics Breakout Room |
Details
The global race for biotechnology has entered a new phase. Around the world, governments are investing in biotechnology not only to improve healthcare, but to strengthen national resilience, economic security and geopolitical competitiveness. From biosecurity and advanced manufacturing to sovereign capability and trusted supply chains, biotechnology is increasingly recognised as strategic infrastructure. As new partnerships emerge between industry, government and defence, this leadership discussion explores how these investments are reshaping innovation, creating new funding and commercialisation pathways, and positioning Australia to become a trusted global partner in the next generation of strategic biotechnology.
Speaker
Dr. Emma Prato
Program Lead - Medical Countermeasures
DMTC Limited
Chair
Mr Mark Reid
Managing Director
Graythan Regulatory Services
Panellist
Dr. Christopher Steele
Chief of Strategy & Business Development
Medical Technology Enterprise Consortium
Panellist